Digital pharmaceutical company WELT announced at CES 2026 that it had unveiled the world's first "AI Convergence Medicine," a new treatment concept that combines existing pharmaceuticals with AI-based digital therapeutics. At the event, WELT presented a case study utilizing the sleep aid "ZolipZ," winning the CES 2026 AI Innovation Award.
AI-integrated medicine is a treatment concept that integrates AI technology to refine the timing and method of administration for each patient, without altering the chemical composition or formulation of the drug. Welt utilizes AgentZ, an AI sleep agent connected to the SleepZ app via a QR code attached to the Zolipz package. This analyzes sleep logs and biosignals, activity levels, lifestyle patterns, and circadian rhythms collected from wearable devices.
Based on this, AI can predict the likelihood of insomnia in advance and guide patients to the most effective medication timing. This encourages medication use only when necessary, minimizing the risk of tolerance and dependence.
Kang Sung-ji, CEO of Welt, explained, “AI-integrated medicine enables patient-centered treatment without changing the drug ingredients,” and “We can improve treatment safety and efficacy through an approach centered on medication timing.”
- See more related articles
You must be logged in to post a comment.